Tier 2 — strong

Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence

Harald Hoensch, Bertram Groh, Lutz Edler, Wilhelm Kirch
World Journal of Gastroenterology 2008 14(14):2187-2193

Bibliography

PubMed
PMID 18407592
PubMed Central
PMC2703843
DOI
10.3748/wjg.14.2187

Study snapshot

DesignProspective cohort comparison
ModelPatients after resection of colorectal neoplasia
Samplen = 87; 31 treated and 56 matched controls
Intervention20 mg apigenin plus 20 mg epigallocatechin gallate daily
DurationApproximately 3-4 years follow-up
EndpointsRecurrence of colorectal neoplasia; Long-term follow-up

What the study showed, in plain terms

This prospective study compared recurrence outcomes in patients receiving a combined flavonoid intervention containing apigenin and EGCG with matched controls.

Key findings

The treated cohort reported fewer recurrent colorectal neoplasias than controls, generating an early clinical signal worth further study.

What this study can and cannot tell us

The study was not a randomized isolated-apigenin trial. Because apigenin was combined with EGCG, any observed effect cannot be attributed to apigenin alone.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology